ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC By Ogkologos - May 21, 2026 43 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TOMBOLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR TILs Therapy Shows Promise in the Management of Anti-PD-1-Resistant Metastatic NSCLC August 23, 2021 Amid Coronavirus Outbreak and Panic Buying, Stores Introduce Special Shopping Times... March 18, 2020 Acing it: The ambitious early career researchers driving progress in cancer... January 21, 2022 ESMO Open: First Official Impact Factor of 5.329 June 30, 2020 Load more HOT NEWS Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer 4 Tips from Oncology Dietitians for Healthier Eating During Cancer Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto A Remarkable Group of Patients with Haematological Disorders with No or...
